Skip to main content

Table 2 Quality assessment of the trials according to the Cochrane Collaboration

From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Trials A B C D E F Total score (n/12)
Blonde 2016 [9] 2 2 1 2 2 1 10
Forst 2014 [10] 2 2 1 1 2 1 9
Neal 2015 [11] 2 1 2 2 2 1 10
Gonzalez 2013 [12] 2 2 1 2 2 1 10
Inagaki 2013 [13] 2 2 1 1 2 1 9
Inagaki 2014 2 1 1 1 2 1 8
Stenlof 2013 [15] 2 1 2 2 2 1 10
Wilding 2013 [16] 2 1 2 2 2 1 10
Yale 2013 [17] 2 1 2 2 2 1 10
Rosenstock 2012 [18] 2 1 2 2 2 1 10
  1. A: sequence generation; B: concealment of allocation; C: Blinding of patients; D: Blinding of caregivers; E: Blinding of outcome assessors; F: Follow-up and intention-to treat analysis